What To Expect From Repligen Corp (RGEN) Q4 2024 Earnings
Repligen Corp (NASDAQ:RGEN) is set to release its Q4 2024 earnings on Feb 20, 2025. The consensus estimate for Q4 2024 revenue is $167.67 million, and the earnings are expected to come in at $0.16 per share.
Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $697.
Repligen: Q4 Earnings Snapshot
Repligen expects full-year earnings in the range of $1.67 to $1.76 per share, with revenue in the range of $685 million to $710 million. This story was generated by Automated Insights ( http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGEN at https://www.zacks.com/ap/RGEN
Repligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Repligen Corp (RGEN) reports robust fourth-quarter revenue growth, driven by product differentiation and strategic initiatives, while setting optimistic guidance for 2025.
Repligen (RGEN) Beats Q4 Earnings Estimates
Repligen (RGEN) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items.
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
Repligen Corp (NASDAQ:RGEN) released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago ...
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repligen (RGEN – Research Report), Springworks ...
Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 80% Above Its Share Price
Key Insights The projected fair value for Repligen is US$264 based on 2 Stage Free Cash Flow to Equity Repligen ...